Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Hold” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned an average rating of “Hold” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.00.

INO has been the subject of several analyst reports. Piper Sandler restated an “overweight” rating and issued a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th. Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.76 on Wednesday. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.06. The stock has a market capitalization of $117.44 million, a PE ratio of -0.68 and a beta of 1.54. Inovio Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.07. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. MCF Advisors LLC purchased a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at $26,000. SG Americas Securities LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $27,000. Nomura Holdings Inc. bought a new stake in shares of Inovio Pharmaceuticals in the 1st quarter worth about $28,000. Stephens Inc. AR purchased a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth about $32,000. Finally, Focus Partners Wealth bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at about $33,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.